Therapeutic drug monitoring‐based dose optimization for imatinib‐associated serious cutaneous reactions in a patient with gastrointestinal stromal tumours: A case report-Reference-Cited by-同舟云学术

Therapeutic drug monitoring‐based dose optimization for imatinib‐associated serious cutaneous reactions in a patient with gastrointestinal stromal tumours: A case report

Published:2020-06 Issue:4 Volume:45 Page:856-862
ISSN:0269-4727
Container-title:Journal of Clinical Pharmacy and Therapeutics
language:en
Short-container-title:J Clin Pharm Ther

Author:

Huang Wanting¹,Li Juan¹,Qiu Feng¹,Wu Xingye²,Zhang Jun²,Li Xuemei¹³,Yao Gaoqiong¹,Zhu Shenyin¹^ORCID

Affiliation:

1. Department of Pharmacy The First Affiliated Hospital of Chongqing Medical University Chongqing China

2. Department of Gastrointestinal Surgery The First Affiliated Hospital of Chongqing Medical University Chongqing China

3. Department of Pharmacy Chongqing Health Center for Women and Children Chongqing China

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcpt.13201

Reference26 articles.

1. Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

2. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor;Trial AR;JAMA,2018

3. The safety profile of imatinib in CML and GIST: long-term considerations

4. Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow‐up;Casali PG;Ann Oncol,2018

5. Clinical and histopathologic analysis of 46 cases of cutaneous adverse reactions to imatinib

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Application of Virtual Therapeutic Drug Monitoring to Assess the Pharmacokinetics of Imatinib in a Chinese Cancer Population Group;Journal of Pharmaceutical Sciences;2023-02

2. C-reactive protein: A promising biomarker for poor prognosis in COVID-19 infection;Clinica Chimica Acta;2020-10

3. Atorvastatin/imatinib interaction;Reactions Weekly;2020-08